Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1971532
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Telomir filed an 8-K, but it's light on details. Watch for more info.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on February 18, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or new developments beyond the standard reporting requirement.
Why It Matters
This filing indicates Telomir Pharmaceuticals has made a regulatory submission, but the lack of specific details means investors cannot yet assess any potential impact on the company.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any new material information, risks, or financial changes.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- February 18, 2025 (date) — Date of Report
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events' being reported.
When was this 8-K filing submitted to the SEC?
The filing was submitted on February 18, 2025.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the IRS Employer Identification Number for Telomir Pharmaceuticals, Inc.?
The IRS Employer Identification Number is 87-2606031.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K being filed?
This Form 8-K is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).